PhD student+31205122480 email@example.com Wim van Harten
Danalyn Byng is an internationally trained epidemiologist and health services researcher. She began working with the NKI in September 2017. Her research involves various interdisciplinary research projects across the complete translational research chain in Health Technology Assessment (HTA). Working closely with Dr. Retèl, she has analyzed the cost-effectiveness of the 70-gene signature, a gene expression profile for breast cancer. She is also conducting analyses on further clinical applications of the 70-gene signature in using data from the MINDACT RCT. As a collaborator within the Cancer Research UK Grand Challenges-funded multinational PRECISION consortium, Danalyn is responsible for a number of HTA and economic evaluation projects. She is investigating the economic feasibility of implementing active surveillance as an alternative to breast surgery for women with low-risk ductal carcinoma in situ (DCIS).